| Vamsi Kiran Kodumuri, | |
|
258 S Chickasaw Trl Ste 203, Orlando, FL 32825-3558 | |
| (407) 303-6588 | |
| Not Available |
| Full Name | Vamsi Kiran Kodumuri |
|---|---|
| Gender | Male |
| Speciality | Interventional Cardiology |
| Experience | 21 Years |
| Location | 258 S Chickasaw Trl Ste 203, Orlando, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003009358 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Adventhealth Orlando | Orlando, FL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Florida Hospital Medical Group Inc | 0749186153 | 1163 |
News Archive
As the role of pharmacies in providing front-line public health services grows, a QUT study has raised concerns that some are not adhering to therapeutic guidelines when distributing pharmaceuticals.
Regenacy Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, today announced a collaboration with the Charcot-Marie-Tooth Association, a registered non-profit organization serving the hereditary neuropathy patient community, to validate the role of HDAC6 in multiple forms of Charcot-Marie-Tooth disease and evaluate the efficacy of ricolinostat, a selective HDAC6 inhibitor, in animal models.
Soligenix, Inc., a development stage biopharmaceutical company, announced today its financial results for the quarter ending March 31, 2012.
Supercharging the mutation rate in cancer cells can create a powerful vaccine that is able to boost the effectiveness of immunotherapy, a major new study reports.
› Verified 2 days ago
| Entity Name | Florida Hospital Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1225034234 PECOS PAC ID: 0749186153 Enrollment ID: O20031208000807 |
News Archive
As the role of pharmacies in providing front-line public health services grows, a QUT study has raised concerns that some are not adhering to therapeutic guidelines when distributing pharmaceuticals.
Regenacy Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, today announced a collaboration with the Charcot-Marie-Tooth Association, a registered non-profit organization serving the hereditary neuropathy patient community, to validate the role of HDAC6 in multiple forms of Charcot-Marie-Tooth disease and evaluate the efficacy of ricolinostat, a selective HDAC6 inhibitor, in animal models.
Soligenix, Inc., a development stage biopharmaceutical company, announced today its financial results for the quarter ending March 31, 2012.
Supercharging the mutation rate in cancer cells can create a powerful vaccine that is able to boost the effectiveness of immunotherapy, a major new study reports.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Vamsi Kiran Kodumuri, 258 S Chickasaw Trl Ste 203, Orlando, FL 32825-3558 Ph: (407) 303-6588 | Vamsi Kiran Kodumuri, 258 S Chickasaw Trl Ste 203, Orlando, FL 32825-3558 Ph: (407) 303-6588 |
News Archive
As the role of pharmacies in providing front-line public health services grows, a QUT study has raised concerns that some are not adhering to therapeutic guidelines when distributing pharmaceuticals.
Regenacy Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, today announced a collaboration with the Charcot-Marie-Tooth Association, a registered non-profit organization serving the hereditary neuropathy patient community, to validate the role of HDAC6 in multiple forms of Charcot-Marie-Tooth disease and evaluate the efficacy of ricolinostat, a selective HDAC6 inhibitor, in animal models.
Soligenix, Inc., a development stage biopharmaceutical company, announced today its financial results for the quarter ending March 31, 2012.
Supercharging the mutation rate in cancer cells can create a powerful vaccine that is able to boost the effectiveness of immunotherapy, a major new study reports.
› Verified 2 days ago
Francoeur Cadet, D.O Internal Medicine Medicare: Medicare Enrolled Practice Location: 232 N Orange Blossom Trl, Orlando, FL 32805 Phone: 407-428-5751 Fax: 407-447-7245 | |
Andrija Vidic, D.O Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 2415 N Orange Ave Ste 700, Orlando, FL 32804 Phone: 407-303-2474 Fax: 407-303-0680 | |
Zain Zamir, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 2501 N Orange Ave Ste 235, Orlando, FL 32804 Phone: 407-303-7169 | |
Dr. Arsenio R Rodriguez, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1745 N Mills Avenue, Orlando, FL 32803 Phone: 407-841-7151 Fax: 407-648-2259 | |
Dr. Maria R Flores, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 70 W Gore St, Suite 100, Orlando, FL 32806 Phone: 407-426-8484 Fax: 404-426-8575 | |
Dr. Fernando Hernandez, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 7243 Della Dr Fl 3, Orlando, FL 32819 Phone: 407-370-8705 |